A Single-center, Open, Self-controlled Design Clinical Study to Evaluate the Pharmacokinetic Effects of Rifampicin or Itraconazole on Single-dose Laolotinib Mesylate Capsules in Healthy Subjects
Latest Information Update: 01 Nov 2022
At a glance
- Drugs Larotinib (Primary) ; Itraconazole; Rifampicin
- Indications Oesophageal cancer; Pancreatic cancer
- Focus Pharmacokinetics
- Sponsors Sunshine Lake Pharma
- 26 Oct 2022 Planned End Date changed from 21 Oct 2022 to 21 Mar 2023.
- 26 Oct 2022 Planned primary completion date changed from 21 Aug 2022 to 21 Jan 2023.
- 05 May 2022 Planned End Date changed from 21 Jun 2022 to 21 Oct 2022.